The U.S. government will pay up to $2.1 billion to Sanofi SA and GlaxoSmithKline PLC to fund the development of a coronavirus vaccine and guarantee supply of 100 million doses, if proven safe and effective in clinical trials, the companies said Friday.
Paris-based Sanofi is leading development of the vaccine, the companies said, and plans to start initial clinical trials in September and move into late-stage studies by the end of this year.
Real Life. Real News. Real Voices
Help us tell more of the stories that matterBecome a founding member
Subscribe to the newsletter news
We hate SPAM and promise to keep your email address safe